

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:

Commissioner for Patents, PO Box 1450, Alexandria VA 22313-1450 on this 34 day of Carlos 300 4

By

(Signature of person mailing)
Patricia Botelho

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Rochelle L. Chaiken, et al

Examiner: Unknown

APPLICATION NO.: 10/727,841

December 4, 2003 :Group Art Unit: 3761

TITLE: Method of Inducing Euglycemia in Diabetic

Patients

Commissioner for Patents

PO Box 1450

FILING DATE:

Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee is thought to be due for this submission. If, however, the Commissioner determines that any fee is due (including any fee for extension, for which petition is hereby made), please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 23, 2004

James T. Jones
Atterney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.

Patent Department, Box 8260-1611

Eastern Point Road Groton, CT 06340 (860) 441-4903

INFORMATION DISCLOSURE CITATION							ATTY. DOCKET NO. PC25464A					SERIAL NO. 10/727,841				
(Use several sheets if necessary)							APPLICANT Rochelle L. Chaiken, et al.									
Rapal 1 of E							FILING DATE December 4, 2003					GROUP 3761				
	/			<u> </u>		U.S	. PATEN	T DOC	JMENTS							
EXAMINER INITIAL	MAR 2 6 2004 LL DOCUMEN		CUMENT NUM	MENT NUMBER			DATE NAME			CLASS	SUBCLASS FILING DAT		DATE OPRIATE			
	/		اد													
		& TH	DEMAN													
				-												
	-															
								_			· · · · ·					
	<u> </u>															
			<u>.</u> ,													
FOREIGN PATENT DOCUMENTS																
DOCUMENT NUMBER								DATE COUNT		DV.	RY CLASS SI		TRANS	SLATION		
								DATE COUNT		NI.	CDASS	SUBCLASS	YES	NO		
/	EP	1	2	7	0	0	1	2	2 Jan 03	EPC)	A61K	38/28	163	NO	
	wo	0	2	0	8	9	9	16	14 Nov 02	PC1	PCT		3/10			
									itle, Date, P			Etc.)				
		Pattor	Patton John S et al., Advanced Drug Delivery Reviews, vol. 35, no. 2-3, Feb 1999, XP 00271139													
./.		Klonot XP 00	ff D. C., D 8005851)iabetes	Technology	and Th	nerapeutics	, Mary An	n Liebert, Larc	chmont NY, U	S, vol.	1, no. 3, 1	999, pgs 307	7-313,		
V		Weiss	S. R. et	al., Diabe	etes Resea	rch and	Clinical Pr	actice, vo	. 50, no. Supl	1, Sept 2000,	pgs S7	74, XP 000	1179580			
/,		Сарре	elleri Jose	ph C et a	al., Diabete	s, vol. 5	50, no. Sup	2, June 2	2001, page A1	08, <i>XP 00090</i>	26481					
✓.		Weiss	Stuart R	et al., Aı	chives of I	nternal i	Medicine, v	ol. 163, n	o. 19, Oct 200	3, pgs 2277-2	282, X	P 0009026	6480			
													•			
														-		
EXAMINER DATE CONSIDERED																
			-	- · ·											T ₁	
EXAMINER: next commun	Initial if r nication to	reference con papplicant.	sidered, whe	ether or not	citation is in co	onformanc	e with MPEP 6	09; Draw line	through citation if	not in conformance	and no	t considered.	Include copy of t	his form	with	